Effect of suloctidil on platelet function in patients with shortened platelet survival time.
The effect of suloctidil (600 mg/day) on platelet survival time (PST) and plasma and urine betathromboglobulin (BTG) was studied in a double-blind, placebo-controlled six-week crossover trial in 13 patients with shortened PST (less than 110 hrs, exponential model). Mean PST after suloctidil (110.6 hrs) was significantly higher than in the placebo phase (94.5 hrs) (p = 0.04). Mean plasma BTG was significantly lower during the suloctidil phase (42.8 ng/ml) compared with the placebo phase (65.8 ng/ml) (p = 0.02), but there was no significant difference in urine BTG. These results suggest that suloctidil provides a platelet protective effect and therefore may be of benefit in reducing the frequency of platelet mediated thromboembolic events.
D001792:Blood Platelets / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006350:Heart Valve Prosthesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000601:surgery; D011183:Postoperative Complications / Q000097:blood / Q000188:drug therapy; D011412:Propanolamines / Q000627:therapeutic use*; D013468:Suloctidil / Q000627:therapeutic use*; D013923:Thromboembolism / Q000097:blood / Q000188:drug therapy*; D001620:beta-Thromboglobulin / Q000378:metabolism
D011412:Propanolamines; D001620:beta-Thromboglobulin; D013468:Suloctidil